Related Experiment Videos
Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
S M Zaacks1, P R Liebson, J E Calvin
1Rush Heart Institute and Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Insights
New biochemical markers and clinical factors are crucial for identifying high-risk patients with unstable coronary syndromes, guiding advanced therapies like glycoprotein IIb/IIIa inhibitors and stents.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- Acute coronary syndromes are common in cardiology practice.
- Unstable angina (UA) and non-Q wave myocardial infarction (NQMI) represent a spectrum with viable myocardium at risk.
- Historically, enzyme differentiation was key for prognosis and therapy in UA and NQMI.
Purpose of the Study:
- To reevaluate unstable coronary syndromes.
- To incorporate new therapies and biochemical markers into risk assessment.
- To identify high-risk patients within the unstable coronary syndromes spectrum.
Main Methods:
- Comprehensive review of peer-reviewed manuscripts from the past three decades.
- Inclusion of recent abstracts for current insights.
- Selection of relevant studies for a focused review.
Main Results:
- The distinction between UA and NQMI is insufficient for high-risk patient identification.
- Electrocardiographic changes, clinical history, biochemical markers, and angiographic findings are superior risk predictors.
- These factors now guide therapeutic decisions for unstable coronary syndromes.
Conclusions:
- Newer therapies, including glycoprotein IIb/IIIa receptor antagonists, low molecular weight heparins, and coronary stents, are indicated for high-risk patients.
- Risk stratification has evolved beyond UA and NQMI differentiation.
- Biochemical markers and clinical assessment are pivotal in managing unstable coronary syndromes.
Objectives:
The goal of this review is to reevaluate the unstable coronary syndromes in the setting of new therapies and biochemical markers.
Background:
Patients with acute coronary syndromes comprise a large subset of many cardiology practices. Patients with unstable angina (UA) and non-Q wave myocardial infarction (NQMI) may sustain a small amount of myocardial loss but have significant amounts of viable, yet ischemic, myocardium, placing them at high risk for future cardiac events. In the past, enzyme differentiation of NQMI from UA was considered important to assess prognosis and direct therapy.
Methods:
Manuscripts published in peer-reviewed journals over the past three decades were reviewed and selected for this review. Recent abstracts were also considered and cited where appropriate.
Results:
In the late 1990's, although UA and NQMI remain parts of a spectrum, it is apparent that the distinction between these two entities is no longer sufficient to identify high risk patients; rather, specific electrocardiographic changes, aspects of the clinical history, newer biochemical markers, and angiographic findings help to better distinguish higher risk individuals from a large patient population with unstable coronary syndromes and these factors usually determine therapy.
Conclusions:
Based on these results, it is likely that newer therapies such as glycoprotein IIb/IIIa receptor antagonists, low molecular weight heparins, and coronary stents will be directed toward these high risk patients.